| 杨自国,朱强,王林,等.曲妥珠单抗与帕妥珠单抗联合紫杉醇在人表皮生长因子受体2阳性乳腺癌新辅助化疗中的疗效及影响因素分析[J].中国临床保健杂志,2026,29(3):378-381. |
| 曲妥珠单抗与帕妥珠单抗联合紫杉醇在人表皮生长因子受体2阳性乳腺癌新辅助化疗中的疗效及影响因素分析 |
| The study on efficacy of neoadjuvant chemotherapy and related factors of in human epidermal growth factor receptor 2-positive breast cancer |
| 投稿时间：2025-11-14 |
| DOI：10.3969/J.issn.1672-6790.2026.03.016 |
| 中文关键词: 乳腺肿瘤 肿瘤治疗方案 新辅助化疗 人表皮生长因子受体2 影响因素分析 |
| 英文关键词: Breast neoplasms Antineoplastic protocols Neoadjuvant therapy Human epidermal growth factor receptor 2 Root cause analysis Fund programs:Young Elite Scientist Sponsorship Program by Bast of Beijing Association for Science and Technology |
| 基金项目:北京市科学技术协会青年人才托举工程项目 |
|
| 摘要点击次数: 166 |
| 全文下载次数: 71 |
| 中文摘要: |
| 目的 探讨对人表皮生长因子受体2(HER-2)阳性的乳腺癌实施不同新辅助化疗的效果,分析影响疗效的相关因素。方法 采用回顾性研究,收集2019年8月至2025年1月首都医科大学附属北京天坛医院收治的98例接受新辅助化疗的HER-2阳性乳腺癌患者的临床资料,其中16例患者接受AC-TPH方案新辅助化疗,具体为:蒽环联合环磷酰胺序贯曲妥珠单抗与帕妥珠单抗联合紫杉醇；63例接受TCbHP方案新辅助化疗,具体为曲妥珠单抗与帕妥珠单抗联合紫杉醇及卡铂方案；19例接受THP方案化疗,具体为曲妥珠单抗与帕妥珠单抗联合紫杉醇方案。结果 98例患者总体完全病理缓解(pCR)率为51.0%。HER-2阳性乳腺癌新辅助化疗疗效与雌激素受体(ER)、孕激素受体(PR)状态相关(P＜0.05)。与患者年龄、肿瘤长径、组织学分级、分期及Ki-67无关(P>0.05)。多因素分析发现ER(+)患者新辅助化疗疗效可能更差(P=0.068)。去蒽环方案组pCR率(57.3%)高于含蒽环组(18.8%),差异有统计学意义(P=0.006),但含铂与不含铂组间pCR率差异无统计学意义(P=0.434)。结论 对HER-2阳性乳腺癌患者实施新辅助化疗,ER阴性患者更易达到pCR。去蒽环方案疗效优于传统含蒽环的化疗方案,而紫杉醇联合曲妥珠单抗/帕妥珠单抗方案并不会因加入卡铂而获益更多。 |
| 英文摘要: |
| Objective To investigate the efficacy of neoadjuvant chemotherapy in human epidermal growth factor receptor 2 (HER-2)-positive breast cancer and analyze factors influencing treatment outcomes.Methods Clinical data of 98 HER-2-positive breast cancer patients who received neoadjuvant chemotherapy at Beijing Tiantan Hospital Affiliated to Capital Medical University,from August 2019 to January 2025 were retrospectively collected.Among them,16 patients received AC-TPH regimen neoadjuvant chemotherapy,specifically:anthracycline combined with cyclophosphamide sequential trastuzumab and pertuzumab combined with paclitaxel;63 cases received neoadjuvant chemotherapy with TCbHP regimen,specifically the combination of trastuzumab and pertuzumab with paclitaxel and carboplatin regimen;19 cases received THP regimen chemotherapy,specifically the combination of trastuzumab and pertuzumab with paclitaxel regimen.Results The overall pCR rate was 51.0%.The pCR rate was associated with ER and PR status (P＜0.05).Age,tumor size,grade,stage,and Ki-67 expression showed no significant correlation with pCR rates (P>0.05).Multivariate analyses shown that ER-positive patients had broadline poorer efficacy (P=0.068).The anthracycline-free regimen group achieved a significantly higher pCR rate (57.3%) than the anthracycline-containing group(18.8%),P=0.006,while no significant difference was observed between platinum-containing and platinum-free regimens(P=0.434).Conclusions In HER-2-positive breast cancer treated with neoadjuvant chemotherapy,ER-negative patients are more likely to achieve pCR.Anthracycline-free regimens have better efficacy than traditional anthracycline-containing chemotherapy regimens in the HER-2-positive breast cancer. |
|
查看全文
|
| 关闭 |
|
|
|